213 related articles for article (PubMed ID: 26252969)
1. Mechanism-based mathematical modeling of combined gemcitabine and birinapant in pancreatic cancer cells.
Zhu X; Straubinger RM; Jusko WJ
J Pharmacokinet Pharmacodyn; 2015 Oct; 42(5):477-96. PubMed ID: 26252969
[TBL] [Abstract][Full Text] [Related]
2. Physiologically-based pharmacokinetic and pharmacodynamic models for gemcitabine and birinapant in pancreatic cancer xenografts.
Zhu X; Trueman S; Straubinger RM; Jusko WJ
J Pharmacokinet Pharmacodyn; 2018 Oct; 45(5):733-746. PubMed ID: 30069744
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamic modeling of synergistic birinapant/paclitaxel interactions in pancreatic cancer cells.
Niu J; Wang X; Qu J; Mager DE; Straubinger RM
BMC Cancer; 2020 Oct; 20(1):1024. PubMed ID: 33097020
[TBL] [Abstract][Full Text] [Related]
4. Birinapant Enhances Gemcitabine's Antitumor Efficacy in Triple-Negative Breast Cancer by Inducing Intrinsic Pathway-Dependent Apoptosis.
Xie X; Lee J; Liu H; Pearson T; Lu AY; Tripathy D; Devi GR; Bartholomeusz C; Ueno NT
Mol Cancer Ther; 2021 Feb; 20(2):296-306. PubMed ID: 33323457
[TBL] [Abstract][Full Text] [Related]
5. Temporal Effects of Combined Birinapant and Paclitaxel on Pancreatic Cancer Cells Investigated
Wang X; Niu J; Li J; Shen X; Shen S; Straubinger RM; Qu J
Mol Cell Proteomics; 2018 Apr; 17(4):655-671. PubMed ID: 29358341
[TBL] [Abstract][Full Text] [Related]
6. Multi-Scale Network Model Supported by Proteomics for Analysis of Combined Gemcitabine and Birinapant Effects in Pancreatic Cancer Cells.
Zhu X; Shen X; Qu J; Straubinger RM; Jusko WJ
CPT Pharmacometrics Syst Pharmacol; 2018 Sep; 7(9):549-561. PubMed ID: 30084546
[TBL] [Abstract][Full Text] [Related]
7. Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer.
Bianco C; Giovannetti E; Ciardiello F; Mey V; Nannizzi S; Tortora G; Troiani T; Pasqualetti F; Eckhardt G; de Liguoro M; Ricciardi S; Del Tacca M; Raben D; Cionini L; Danesi R
Clin Cancer Res; 2006 Dec; 12(23):7099-107. PubMed ID: 17145834
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamic modeling of combined chemotherapeutic effects predicts synergistic activity of gemcitabine and trabectedin in pancreatic cancer cells.
Miao X; Koch G; Straubinger RM; Jusko WJ
Cancer Chemother Pharmacol; 2016 Jan; 77(1):181-93. PubMed ID: 26604207
[TBL] [Abstract][Full Text] [Related]
9. Induction of growth inhibition and apoptosis in pancreatic cancer cells by auristatin-PE and gemcitabine.
Li Y; Singh B; Ali N; Sarkar FH
Int J Mol Med; 1999 Jun; 3(6):647-53. PubMed ID: 10341297
[TBL] [Abstract][Full Text] [Related]
10. Triciribine Phosphate Monohydrate, an AKT Inhibitor, Enhances Gemcitabine Activity in Pancreatic Cancer Cells.
Kim R; Yamauchi T; Husain K; Sebti S; Malafa M
Anticancer Res; 2015 Sep; 35(9):4599-604. PubMed ID: 26254348
[TBL] [Abstract][Full Text] [Related]
11. Synergistic Pharmacodynamic Effects of Gemcitabine and Fibroblast Growth Factor Receptor Inhibitors on Pancreatic Cancer Cell Cycle Kinetics and Proliferation.
Lin Q; Qian Z; Jusko WJ; Mager DE; Ma WW; Straubinger RM
J Pharmacol Exp Ther; 2021 Jun; 377(3):370-384. PubMed ID: 33753538
[TBL] [Abstract][Full Text] [Related]
12. Demethylzeylasteral (ZST93) inhibits cell growth and enhances cell chemosensitivity to gemcitabine in human pancreatic cancer cells via apoptotic and autophagic pathways.
Wang F; Tian X; Zhang Z; Ma Y; Xie X; Liang J; Yang C; Yang Y
Int J Cancer; 2018 May; 142(9):1938-1951. PubMed ID: 29238973
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamic modeling of cell cycle and apoptotic effects of gemcitabine on pancreatic adenocarcinoma cells.
Hamed SS; Straubinger RM; Jusko WJ
Cancer Chemother Pharmacol; 2013 Sep; 72(3):553-63. PubMed ID: 23835677
[TBL] [Abstract][Full Text] [Related]
14. Assessment of Three-Drug Combination Pharmacodynamic Interactions in Pancreatic Cancer Cells.
Molins EAG; Jusko WJ
AAPS J; 2018 Jun; 20(5):80. PubMed ID: 29951754
[TBL] [Abstract][Full Text] [Related]
15. Patient-derived glioblastoma cells show significant heterogeneity in treatment responses to the inhibitor-of-apoptosis-protein antagonist birinapant.
Zakaria Z; Tivnan A; Flanagan L; Murray DW; Salvucci M; Stringer BW; Day BW; Boyd AW; Kögel D; Rehm M; O'Brien DF; Byrne AT; Prehn JH
Br J Cancer; 2016 Jan; 114(2):188-98. PubMed ID: 26657652
[TBL] [Abstract][Full Text] [Related]
16. Systems Pharmacodynamic Model of Combined Gemcitabine and Trabectedin in Pancreatic Cancer Cells. Part II: Cell Cycle, DNA Damage Response, and Apoptosis Pathways.
Miao X; Koch G; Shen S; Wang X; Li J; Shen X; Qu J; Straubinger RM; Jusko WJ
J Pharm Sci; 2024 Jan; 113(1):235-245. PubMed ID: 37918792
[TBL] [Abstract][Full Text] [Related]
17. Effect of a combination of S-1 and gemcitabine on cell cycle regulation in pancreatic cancer cell lines.
Morimoto Y; Takeuchi O; Takizawa A; Yoneyama H; Asanuma F; Suzuki Y; Atsuda K; Yamada Y
Anticancer Drugs; 2012 Jun; 23(5):505-14. PubMed ID: 22334000
[TBL] [Abstract][Full Text] [Related]
18. Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer.
Banerjee S; Zhang Y; Ali S; Bhuiyan M; Wang Z; Chiao PJ; Philip PA; Abbruzzese J; Sarkar FH
Cancer Res; 2005 Oct; 65(19):9064-72. PubMed ID: 16204081
[TBL] [Abstract][Full Text] [Related]
19. Synergistic effects of baicalein with gemcitabine or docetaxel on the proliferation, migration and apoptosis of pancreatic cancer cells.
Liu P; Feng J; Sun M; Yuan W; Xiao R; Xiong J; Huang X; Xiong M; Chen W; Yu X; Sun Q; Zhao X; Zhang Q; Shao L
Int J Oncol; 2017 Dec; 51(6):1878-1886. PubMed ID: 29039524
[TBL] [Abstract][Full Text] [Related]
20. Ceramide regulates gemcitabine-induced senescence and apoptosis in human pancreatic cancer cell lines.
Modrak DE; Leon E; Goldenberg DM; Gold DV
Mol Cancer Res; 2009 Jun; 7(6):890-6. PubMed ID: 19531570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
